Patients TMS works. Why do fewer than 1% of eligible patients get it? A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
News Lilly buys into psychedelics with $3.8bn AtaiBeckley deal AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.
News J&J seeks to rewrite the script on depression treatment A survey has found that most patients with depression have little hope of being free of their symptoms, and Johnson & Johnson aims to change that.
Patients Exploring mixed episodes in bipolar I disorder: When mania a... One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
News Alto raises $120m for resistant depression programme Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
News NHS study will pick apart mental illness with data science Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.